Application of calcium ion/calmodulin-dependent protein kinase II delta

• Main Authors: LI MENGYUAN, XU RONGZHEN, WU ZHAOXING, ZHANG XUZHAO, GONG QINYUAN
• Format: Patent
• Language: Chinese; English
• Published: 21.04.2023
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS OR TEST PAPERS THEREFOR; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES; ENZYMOLOGY; INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES; MEASURING; MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS; METALLURGY; MICROBIOLOGY; MUTATION OR GENETIC ENGINEERING; PHYSICS; PROCESSES OF PREPARING SUCH COMPOSITIONS; SPIRITS; TESTING; VINEGAR; WINE

The invention provides application of calcium ion/calmodulin-dependent protein kinase II delta, application of the protein kinase II delta in preparation of drugs for diagnosing and treating cancers, and a sequence of the protein kinase II delta. The research shows that the protein kinase II delta-3 is an important carcinogenic kinase of acute myelogenous leukemia and is abnormally highly expressed in an AML sample, the survival prognosis of a high-expression group is poor, and the difference has statistical significance. The protein kinase II delta is selectively and highly expressed in AML cells and LSCs, and is low or not expressed in normal human hematopoietic stem cells and peripheral blood cells. The silent protein kinase II delta causes growth arrest, cell apoptosis increase and G0/G1 phase retardation of AML stem/progenitor cells, and after overexpression of the protein kinase II delta, the proliferation ability of the AML cells is significantly enhanced; compared with a control group, the activity of